Deciphering the ways in which somatic mutations and germline susceptibility variants cooperate to promote cancer is challenging. Ewing sarcoma is characterized by fusions between EWSR1 and members of the ETS gene family, usually EWSR1-FLI1, leading to the generation of oncogenic transcription factors that bind DNA at GGAA motifs 1-3 . A recent genome-wide association study 4 identified susceptibility variants near EGR2. Here we found that EGR2 knockdown inhibited proliferation, clonogenicity and spheroidal growth in vitro and induced regression of Ewing sarcoma xenografts. Targeted germline deep sequencing of the EGR2 locus in affected subjects and controls identified 291 Ewing-associated SNPs. At rs79965208, the A risk allele connected adjacent GGAA repeats by converting an interspaced GGAT motif into a GGAA motif, thereby increasing the number of consecutive GGAA motifs and thus the EWSR1-FLI1-dependent enhancer activity of this sequence, with epigenetic characteristics of an active regulatory element. EWSR1-FLI1 preferentially bound to the A risk allele, which increased global and allele-specific EGR2 expression. Collectively, our findings establish cooperation between a dominant oncogene and a susceptibility variant that regulates a major driver of Ewing sarcomagenesis.
Ewing sarcoma is an aggressive pediatric malignancy that likely arises from neural crest-or mesoderm-derived mesenchymal stem cells (MSCs) 5, 6 . It is driven by oncogenic fusions between EWSR1 and genes in the ETS family (mostly FLI1) 1, 7 . EWSR1-FLI1 binds DNA either at ETS-like consensus sites containing a GGAA core motif or, more specifically with respect to other ETS family members, at GGAA microsatellites, where the enhancer activity increases with the number of consecutive GGAA motifs 2, 3 . Notably, ~40% of EWSR1-FLI1 binding occupancy maps to GGAA microsatellites 8 . Aside from EWSR1-FLI1, Ewing sarcoma is known for its paucity of recurrent somatic abnormalities [9] [10] [11] .
Epidemiological studies have documented striking disparities in the incidence of Ewing sarcoma across human populations 12 , implying a strong contribution of germline variation to Ewing sarcoma tumorigenesis. Our recent genome-wide association study (GWAS) identified three significant susceptibility loci with higher odds ratios (ORs) than commonly observed in adult cancers (OR > 1.5, compared with OR < 1.3 for adult cancers) 4, 13 . However, the potential oncogenic cooperation between the major EWSR1-FLI1 somatic alteration and these Ewing sarcoma susceptibility loci remains to be elucidated. Here we focused on the chr10q21.3 susceptibility locus, which harbors two plausible candidate genes, ADO (2-aminoethanethiol dioxygenase), encoding a non-heme iron enzyme that converts cysteamine into taurine 14 , and EGR2 (early growth response 2; also known as KROX20), encoding a conserved zinc-finger transcription factor that promotes proliferation, differentiation and/or survival in different cell types, including neural crest-derived Schwann cells and mesoderm-derived osteoprogenitors 15, 16 . Previous data showed that ADO and EGR2 are overexpressed in Ewing sarcoma compared with other solid tumors Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite 1 0 7 4 VOLUME 47 | NUMBER 9 | SEPTEMBER 2015 Nature GeNetics l e t t e r s and that their elevated expression is associated with risk alleles 4 . EGR2 and, to a lesser extent, ADO are also strongly overexpressed in Ewing sarcoma relative to their expression in normal tissues ( Fig. 1a and Supplementary Fig. 1 ). Comparative analysis of microarray data from seven pediatric soft tissue and brain tumor types showed that EGR2, but not ADO, clusters with established EWSR1-FLI1 target genes 17 ( Fig. 1b) . To further explore the expression quantitative trait locus (eQTL) properties of the Ewing sarcoma chr10 susceptibility locus, we evaluated available genotype and matched expression data sets from Ewing sarcoma and other small-round-cell tumors, as well as from normal tissues 4, [18] [19] [20] [21] [22] [23] . Interestingly, the Ewing sarcoma risk-associated rs1848797, which was genotyped in all data sets, was associated with higher EGR2 and ADO expression only in Ewing sarcoma, and not in EWSR1-FLI1-negative tissues ( Table 1 , Supplementary Data and Supplementary Fig. 2 ). Moreover, ectopic EWSR1-FLI1 expression in human MSCs specifically induced EGR2 expression (Fig. 1c) , whereas EWSR1-FLI1 knockdown by specific small interfering RNA (siRNA) consistently reduced EGR2 expression in four different Ewing sarcoma cell lines (Supplementary Fig. 3 ). Such regulation by EWSR1-FLI1 was not observed for ADO. These data strongly suggest that EGR2 and ADO are specifically regulated by eQTLs in Ewing sarcoma, but that only EGR2 is EWSR1-FLI1 dependent.
Knockdown experiments showed that inhibition of EGR2, but not of ADO, impaired the proliferation and clonogenicity of four different Ewing sarcoma cell lines, reduced cell cycle progression through S-phase and reduced cell viability (Fig. 2a,b and Supplementary  Fig. 4 ). To confirm the contribution of EGR2 to Ewing sarcoma growth, we generated Ewing sarcoma cell lines with a doxycyclineinducible anti-EGR2 small-hairpin RNA (shRNA) expression system. Long-term EGR2 knockdown not only dramatically reduced anchorage-independent spheroidal growth in vitro but, even more strikingly, also induced the regression of Ewing sarcoma xenografts in vivo (Fig. 2c,d) . Consistent with the hypothesis that EGR2 acts downstream of EWSR1-FLI1, transcriptome profiling of Ewing sarcoma cells after knockdown of either gene showed highly significantly overlapping transcriptional signatures ( Fig. 2e and Supplementary Data). Collectively, these data suggest that EGR2 is an EWSR1-FLI1-induced target gene critical for Ewing sarcoma tumorigenicity.
As several reports have shown that EGR2 acts downstream of the epidermal growth factor (EGF) and fibroblast growth factor (FGF) pathway 15, 24, 25 , we explored a potential contribution of these pathways to Ewing sarcoma growth and EGR2 regulation. Whereas EGF receptors (EGFRs) are minimally expressed in Ewing sarcoma, some FGF receptors (FGFRs), particularly FGFR1, are highly expressed (Supplementary Fig. 5a ). Consistently, bFGF, but not EGF, strongly induced both proliferation of and EGR2 expression in Ewing sarcoma cells (Supplementary Fig. 5b,c) . These data indicate that EWSR1-FLI1 and FGF signaling converge to upregulate the expression of EGR2.
To fine-map the chr10 susceptibility locus and to identify variants that potentially contribute to EGR2 overexpression, we performed targeted deep sequencing across the chr10 susceptibility locus, including the flanking haplotype blocks, in the germline DNA of 343 individuals with Ewing sarcoma and 251 genetically matched controls (median target-region coverage ≥ 10×, 91.35%; median nucleotide coverage, 217×). Genetic matching was based on principal-component analysis 4 of SNP array data (Supplementary Fig. 6 ). After quality control metrics had been applied to the sequencing data (for example, ≥10× coverage per position, genotype call rate of ≥90% and compliance with Hardy-Weinberg equilibrium), 290 common SNPs (minor allele frequency > 0.05) were identified that were significantly associated with Ewing sarcoma (P < 0.05; Fig. 3a , Supplementary Data and Supplementary Fig. 7 ). These included all 14 sentinel SNPs reported in our previous GWAS 4 . Haplotype and linkage disequilibrium (LD) analysis showed that this locus consists of discrete subhaploblocks ( Fig. 3a and Supplementary Data) . Figure 1 EGR2 overexpression is mediated by EWSR1-FLI1. (a) EGR2 and ADO expression levels in Ewing sarcoma (EwS, GSE34620) and normal tissue (GSE3526). The normal-body atlas consisted of 353 microarrays representing 63 individual tissue types (supplementary Fig. 1 ). Data are shown as medians (horizontal bars) with ranges for the 25th-75th percentile (box) and 10th-90th percentile (whiskers). P values determined via two-tailed unpaired Student's t-test with Welch's correction. (b) Between-group analysis. Genes (gray dots) and tumor samples (colored spheres) are separated along three axes. EwS, Ewing sarcoma (n = 279); RMS, rhabdomyosarcoma (n = 121); OS, osteosarcoma (n = 25); DSRCT, desmoplastic smallround-cell tumor (n = 32); MB, medulloblastoma (n = 52); NB, neuroblastoma (n = 64); MRT, malignant rhabdoid tumor (n = 35). The main genes specifically overexpressed in Ewing sarcoma are indicated. (c) Quantitative real-time PCR analysis of EGR2 and ADO expression in human MSC lines L87 and V54-2 after ectopic EWSR1-FLI1 expression (pEWSR1-FLI1) as compared with empty vector (pControl). Data are shown as the mean and s.e.m.; n ≥ 9 independent experiments. The EWSR1-FLI1 targets NR0B1 and PRKCB served as positive controls 17, 35 . EWSR1-FLI1 expression was confirmed by immunoblot (loading control: β-actin). npg l e t t e r s
To prioritize SNPs for functional assessment, we crossed our sequencing data with published chromatin immunoprecipitation (ChIP)-Seq, DNase-Seq and ENCODE data, with particular focus on Ewing sarcoma cell lines 8, 26, 27 , as recent studies have suggested that most causal SNPs cluster in epigenetically active and celltype-specific regulatory elements 28, 29 (Fig. 3a) . We also included data on conserved EGR2 regulatory elements previously mapped in animal models 30 ( Fig. 3a and Supplementary Fig. 8 ). We observed activating chromatin marks, signals for formaldehyde-assisted isolation of regulatory elements (FAIRE) and/or DNaseI hypersensitivity at five main loci: two loci corresponding to known EGR2 regulatory elements (MSE (myelinating Schwann cell enhancer) 30 and BoneE (bone enhancer) (unpublished data); Supplementary  Fig. 8 ), one to the ADO promoter, and two to GGAA microsatellites (mSat1 and mSat2) that overlapped with EWSR1-FLI1 ChIPSeq signals (Fig. 3a) . Because the ADO promoter does not contain Ewing sarcoma-associated SNPs, it was not further investigated. Luciferase reporter assays indicated that BoneE and MSE had no and weak activity in Ewing sarcoma, respectively (Fig. 3b,c) . In contrast, both GGAA microsatellites exhibited strong EWSR1-FLI1-dependent enhancer-like activity (Fig. 3b,c) . This activity corresponded to EWSR1-FLI1-dependent activating chromatin marks H3K4me1 and H3K27ac (Fig. 3a) and was consistent with recent evidence suggesting that EWSR1-FLI1 can act as a pioneer transcription factor to create de novo enhancers at GGAA microsatellites 27 .
Because of its observed higher enhancer activity, relatively simpler structure compared with that of mSat1, and localization in the subhaploblock containing some of the most significant Ewing sarcomaassociated SNPs (Figs. 3a and 4a and Supplementary Fig. 9 ), we focused on mSat2 and carried out PCR-based targeted long-read (300/300 nt) deep resequencing of all samples to analyze its genetic architecture. This yielded 1,158 analyzable mSat2 sequences, which revealed another SNP, rs79965208, in strong LD (D′ = 0.97) with the nearby rs6479860, one of the strongest sentinel SNPs from our GWAS 4 ( Fig. 4a and Supplementary Data) . The significant association of the A allele of rs79965208 with Ewing sarcoma (P = 0.022, logistic regression) was replicated in two independent cohorts, the first based on direct sequencing of this SNP in 156 additional Ewing sarcoma subjects and 184 controls of European descent (P = 6.15 × 10 −3 , logistic regression), and the second on imputation from the 1000 Genomes Project Phase 3 reference panel 31 of 162 individuals with first primary Ewing sarcoma from the Childhood Cancer Survivor Study 32 genotyped on Illumina HumanOmni5Exome arrays and 435 cancerfree controls from the Division of Cancer Epidemiology and Genetics (P = 9.33 × 10 −6 , logistic regression) (Supplementary Data).
Interestingly, rs79965208 converts a GGAT motif into a GGAA motif, thereby connecting two adjacent GGAA repeats (Fig. 4a) . The first GGAA repeat is polymorphic and contains a median number of 11 GGAA motifs, whereas the second is not polymorphic and is composed of four GGAA motifs. The A allele at rs79965208 therefore increases the median number of consecutive GGAA motifs from 11 to 16.
The previously described threshold for exponentially increasing EWSR1-FLI1-dependent enhancer activity is >12 consecutive GGAA motifs 3 . In the current study, a significantly larger proportion of Ewing sarcoma mSat2 sequences contained >12 GGAA motifs than did controls (65.88% versus 54.99%, P = 2.10 × 10 −6 , two-tailed Fisher's exact test). We subsequently examined the enhancer properties of mSat2 corresponding to the reference sequence (hg19) containing either the T or the A allele at rs79965208 in a luciferase assay. Relative to the T allele, the A allele increased the EWSR1-FLI1-induced enhancer npg l e t t e r s activity of mSat2 (Fig. 4b) . This transcription-activation property was observed in two Ewing sarcoma cell lines and was strictly dependent on EWSR1-FLI1, as its doxycycline-induced knockdown abrogated luciferase activity (Fig. 4b) .
In accordance with the reporter assays, the A allele was associated with significantly higher EGR2 expression in Ewing sarcoma tumors (Fig. 4c) . Consistently, ChIP experiments in the A/T Ewing sarcoma cell line MHH-ES1 using a specific antibody to FLI1 followed by (Fig. 4d and Supplementary Fig. 10 ), indicating that EWSR1-FLI1 preferentially bound to the A allele of rs79965208. Moreover, taking advantage of a transcribed SNP in the 3′ UTR of EGR2 (rs61865883), we assessed allele-specific EGR2 expression via targeted RNA deep sequencing. Across 45 individuals with heterozygosity for rs61865883, the transcriptional allelic imbalance was significantly higher in 16 tumors heterozygous for rs79965208 (A/T) than in 29 tumors homozygous (A/A or T/T) for this locus (Fig. 4e) . Collectively, our results show that EGR2 is a Ewing sarcoma susceptibility gene whose overexpression in tumors is mediated by EWSR1-FLI1 through a risk-conferring enhancer-like polymorphic GGAA microsatellite (Fig. 4f) .
Importantly, we noted that the chr10 signal was strongly reduced when we performed association testing conditionally on rs79965208, which indicated that this SNP is a major functional variant at this locus. However, some association signal was still observed, so it remains plausible that other SNPs could also have a regulatory effect on EGR2 expression through other mechanisms ( Supplementary  Fig. 11 ). The relatively low EGR2 expression observed in some Ewing sarcoma cases, particularly in cases with the T/T genotype, suggests that EGR2 might not always be absolutely necessary for Ewing sarcoma growth, and that growth may thus rely on alternative 'transformation-facilitating genes' , possibly linked to other Ewing sarcoma susceptibility loci. However, we could not test whether Ewing sarcoma cells with a T/T genotype at rs79965208 have decreased sensitivity to EGR2 knockdown, as the T/T genotype was not observed across 21 different Ewing sarcoma cell lines (Supplementary Data).
As the incidence of Ewing sarcoma is higher in Europeans than in Africans 12 , we investigated the frequency of the A allele at rs79965208 across human populations, as determined by the 1000 Genomes Project 31 (Supplementary Data). Strikingly, the A risk allele is highly significantly more frequent in non-African human populations (mean, 0.64; range, 0.57-0.70; n = 1,886) than in Africans (0.25; n = 691) (P = 2.20 × 10 −16 , Fisher's exact test), which suggests that rs79965208 underwent a recent expansion in non-Africans and that it might contribute to the variable susceptibility to Ewing sarcoma across populations.
To our knowledge, this constitutes one of the first reports of how a germline variant highly correlated with the reported GWAS signal can inform our understanding of a cancer-specific acquired genetic abnormality 22 . Furthermore, our findings are in line with predictions that causal variants are not necessarily among the most significant variations leading to the identification of the susceptibility loci, but rather are in strong LD with them 33, 34 . Moreover, they illustrate the contribution of a common germline variant that alters one or more key biological pathways in Ewing sarcoma through the modification of transcription regulatory elements that mediate the effects of a dominant oncogene 13 .
URLs. https://www.addgene.org/21915/; http://www.gtexportal. org/home/; http://www.r-project.org/; https://github.com/jstjohn/ SeqPrep; http://broadinstitute.github.io/picard/; http://www.clustal. org/omega/.
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Methods and any associated references are available in the online version of the paper.
Accession codes. Primary microarray data are compliant with the MIAME guidelines and were deposited at the Gene Expression Omnibus (GEO) under accession GSE62090. 39, 40 . Cells were grown at 37 °C in 5% CO 2 in a humidified atmosphere in RPMI 1640 medium (Gibco) containing 10% FCS (Eurobio), 100 U/ml penicillin and 100 µg/ml streptomycin (Gibco). Cell line purity and authenticity were confirmed by deep sequencing of susceptibility loci and short tandem repeat profiling. Cells were checked routinely by PCR for the absence of mycoplasma.
Transient transfection.
Cells were seeded at a density of 1 × 10 5 to 2 × 10 5 per well of a six-well plate in a volume of 2.1 ml medium. Cell numbers were adjusted accordingly for transfection in larger or smaller volumes, and cells were transfected with siRNA (15 nM) with RNAiMAX (Invitrogen). The Qiagen AllStars Negative Control non-targeting siRNA was used as a control. siRNAs are listed in the Supplementary Data. For transfection with plasmids, 3 × 10 5 cells per well of a six-well plate were seeded in 2.5 ml medium and transfected with Lipofectamine LTX and Plus Reagent (Invitrogen). The pCDH1-MCS1-Puro (pControl) (System Biosciences) and the pCDH1-EWSR1-FLI1 (pEWSR1-FLI1) vectors were described previously 3, 35 .
Doxycycline-inducible shRNA constructs. Negative-control and specific shRNAs against EGR2 were purchased from Sigma-Aldrich (Supplementary Data) and cloned into the pLKO-Tet-On all-in-one system 41 (Addgene). Lentivirus was produced in HEK293T cells (from ATCC). SK-N-MC and POE cells were infected with a multiplicity of infection of 10 and selected for 7 d using 1-2 µg/ml puromycin (Invitrogen). Puromycin-resistant clones were grown from single cells. Knockdown efficacy was assessed in individual clones by quantitative real-time PCR (qRT-PCR) 96 h after the addition of doxycycline (1 µg/ml).
RNA extraction, reverse transcription and qRT-PCR. RNA was extracted with the Nucleospin II kit (Macherey-Nagel) and reverse-transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). PCRs were performed either using TaqMan assays with qRT-PCR Mastermix Plus without UNG (Eurogentec) or using SYBR green (Applied Biosystems). Oligonucleotides were purchased from MWG Eurofins Genomics (Supplementary Data). Reactions were run on an ABI/PRISM 7500 instrument and analyzed using the 7500 system SDS software (Applied Biosystems).
DNA microarrays.
RNA from A673 and SK-N-MC cells was extracted 48 h after transfection with siRNA. RNA quality was checked with a Bioanalyzer (Agilent). Total RNA (200 ng) was amplified and labeled with the Affymetrix GeneChip Whole Transcript Sense Target Labeling Kit. Antisense copy RNA was hybridized on Affymetrix Human Gene 2.1 ST arrays. Data were normalized by means of Probe Logarithmic Intensity Error (PLIER) estimation and custom brainarray CDF (v16) 42 , are compliant with the MIAME guidelines, and were deposited in the Gene Expression Omnibus (GEO; GSE62090). eQTL analyses. Microarray data retrieved from GEO were normalized by robust multiarray averaging using custom brainarray CDF (v18) 42 . Accession codes are listed in the Supplementary Data. Matched genotype data for rs1848797 were retrieved from the series-matrix files of the original studies, except for the neuroblastoma and LCL data sets, for which genotypes were kindly provided by J. Maris (Children's Hospital of Philadelphia, Pennsylvania, USA) or by L. Liang (Harvard School of Public Health, Boston, Massachusetts, USA) and W. Cookson (Imperial College, London, UK). Additionally, the Broad GTEx database 23 was assessed for associations of EGR2 and ADO expression with the genotypes at rs1848797 (data censoring: July 8, 2014; 13 normal tissue types with at least 60 samples per tissue type, amounting to 1,421 samples). P values of linear regressions are reported.
Between-group analysis (BGA). BGA was performed as described 35 . In total, 279 Ewing sarcomas (GSE34620, GSE34800, GSE12102, and unpublished data), together with 32 desmoplastic small-round-cell tumors (unpublished data), 52 medulloblastomas (GSE12992 and unpublished data), 64 neuroblastomas (GSE12460 and unpublished data), 121 rhabdomyosarcomas (E-TABM-1202 and unpublished data), 35 malignant rhabdoid tumors (unpublished data) and 25 osteosarcomas (GSE14827), were included in the BGA, which was carried out with the made4 R package 43 . All microarray data were generated on Affymetrix HG-U133Plus2.0 arrays and simultaneously normalized using the gcrma package version 2.18.1 in R.
Immunoblots. Immunoblots were done with rabbit polyclonal anti-EGR2 (1/2,000, PRB-236P, Covance), mouse monoclonal anti-FLI1 (1:5,000, clone 7.3) 44 , rabbit polyclonal anti-FLI1 (1:250, RB-9295-PCL, Thermo Scientific), rabbit monoclonal anti-ADO (1:1,000, EPR6581, Abcam), mouse monoclonal anti-α-tubulin (1:10,000, DM1A, Sigma-Aldrich), and mouse monoclonal anti-β-actin (1:10,000, A-5316, Sigma-Aldrich). Then membranes were incubated with an anti-rabbit or anti-mouse immunoglobulin G (IgG) horseradish peroxidase-coupled secondary antibody (1:3,000, NA934 or NXA931, respectively; Amersham Biosciences). Proteins were detected by enhanced chemiluminescence (Pierce).
Sequence alignments. Mouse and human DNA sequences of EGR2 enhancers were aligned using Clustal Ω (v1.2.0) 45 . Analysis of cell cycle and apoptosis. Cell cycle phases were analyzed using propidium iodide (PI) (Sigma-Aldrich). 96 h after transfection with siRNA, cells (including supernatant) were harvested, fixed in 70% ethanol at 4 °C, and stained with PI solution (40 µg/ml, with 100 µg/ml RNase A). For analysis of apoptosis, cells (including supernatant) were harvested 96 h after transfection and stained with the Annexin-V-FITC/PI Apoptosis Detection Kit II (Becton Dickinson). Samples were assayed on an LSR II flow cytometer (Becton Dickinson). Data were analyzed with FlowJo software (TreeStar).
Clonogenic growth assays. Assays were performed essentially as described 46 . Depending on the cell line, 1.5 × 10 3 to 3 × 10 3 cells per well of a 12-well plate were seeded in 1 ml medium containing 5% FCS for A673 cells and 10% FCS for SK-N-MC, EW7 and POE cells. Cells were transfected with siRNA 24 h after seeding and re-transfected every 96 h. After 9-14 d, colonies were methanol-fixed and stained with crystal violet. Colony number and area were quantified on scanned plates with ImageJ. Relative clonogenicity is reported as the product of the colony number and the average colony size.
Spheroidal growth assays. 2 × 10 2 cells per well of a 96-well plate were seeded in 120 µl in an equal mix of 10% FCS-containing RPMI 1640 medium and AIM-V medium (Gibco) in plates covered with attachment-preventing poly-2-hydroxyethyl-metacrylate (20 mg/ml PolyHEMA, Sigma-Aldrich). Doxycycline (1 µg/ml) was added for the induction of EGR2 knockdown. We used the following clones: SK-N-MC shControl#19, shEGR2_4#31, shEGR2_5#2, POE shControl21b, shEGR2_4#22, and shEGR2_5#2. After 9-11 d, spheres were documented by phase-contrast microscopy (four individual images per well; octaplicates per group). Images were analyzed with ImageJ. The relative sphere-formation capacity is reported as the product of the sphere number and the average sphere size.
DNA constructs and mutagenesis. Human elements mSat1, mSat2, MSE and BoneE were PCR cloned using the primers listed in the Supplementary Data into the pGL3-luc vector (Promega) upstream of the SV40 minimal promoter. T-to-A mutagenesis of mSat2 at rs79965208 was done with the QuickChange Mutagenesis Kit (Clontech).
Reporter assays and constructs. A673-TR-shEF1 and SK-N-MC-TR-shEF1 (ref. 38) were transfected with pGL3-luc vectors and Renilla pGL3-Rluc (ratio, 100:1). After 4 h, transfection media were replaced by media with or without doxycycline (1 µg/ml). Cells were lysed after 48 h and assayed with a dual luciferase assay system (Promega). Firefly luciferase activity was normalized to Renilla luciferase activity.
Chromatin immunoprecipitation. ChIP was done with rabbit polyclonal anti-FLI1 (C19-X, Santa Cruz Biotechnology) or a rabbit IgG control in MHH-ES1 cells using the iDeal ChIP-Seq Kit for Transcription Factors (Diagenode). DNA was sheared to an average size of 500 bp to enable mSat2 PCR amplification followed by deep sequencing in an Illumina MiSeq instrument (>42,000×). ChIP efficacy was validated by qRT-PCR using a CCND1 EWSR1-FLI1 binding site 47 (positive control) and an intronic CCND1 locus (negative control; Supplementary  Fig. 10 ). Primers are listed in the Supplementary Data. Xenotransplantation experiments and mice. 8 × 10 6 POE or 15 × 10 6 SK-N-MC cells containing either a doxycycline-inducible negative control shRNA (POE shControl#21b or SK-N-MC shControl#19) or a specific shRNA against EGR2 (POE shEGR2_4#22 or SK-N-MC shEGR2_4#31) were injected subcutaneously in the flanks of 6-week-old female C.B-17/SCID mice (Charles River Laboratories) in an equal mix of PBS and Matrigel (BD Biosciences). When tumors reached a volume of 75-100 mm 3 , mice were randomly assigned to either the control (5% sucrose in drinking water) or the treatment (doxycycline (2 mg/l) and 5% sucrose in drinking water) group. Tumor growth was monitored with a caliper every 2-3 d. Mice were killed once tumors reached a volume of 1,500 mm 3 , calculated as V = a × b 2 /2, with a being the largest diameter and b the smallest. Doxycycline-induced EGR2 knockdown was confirmed by qRT-PCR 72 h after the start of doxycycline treatment in aliquots of the injected cells that were grown in parallel in vitro. Experiments were conducted in accordance with the recommendations of the European Community (86/609/EEC), the French Competent Authority, and UKCCCR (guidelines for the welfare and use of animals in cancer research). The sample size was not predetermined.
Human samples. Ewing sarcoma patients from France have been referred to the Institut Curie Hospital for molecular diagnosis since 1990. All subjects included in this study had a specific EWSR1-ETS fusion. Constitutional DNA of adequate quality was available for 343 subjects. This study received approval by institutional review boards and ethics committees (Comité de Protection des Personnes Ile-de-France I). Consent was obtained through communication with patients or families either by the referring oncologists or by the Institut Curie Unité de Génétique Somatique. Genomic DNA was isolated from bone marrow or blood via proteinase K lysis and a phenol chloroform extraction method. We included control samples from 251 French subjects originally obtained as part of the Cancer Genetic Markers of Susceptibility (CGEMS) prostate cancer project 48 . All control subjects were male and recruited in the geographical areas close to Paris, Nancy and Brest through participation in a systematic health-screening program funded by the French National Health Insurance. All controls were determined to be unaffected by cancer through medical examination and blood tests for prostate-specific antigen. The sample size was not predetermined.
Analysis of population substructure. Principal-component analysis (PCA) was performed as described 4 to select genetically matching cases and controls for sequencing and association testing. To ensure genetic homogeneity in populations of affected subjects and controls, we used an EM-fitted Gaussian mixture clustering method assuming one cluster and noise to exclude isolated subjects (Supplementary Fig. 6 ). Noise was initialized by the NNclean function in the prabclus R package, which determines whether data points are noise or part of a cluster on the basis of a Poisson process model. This was followed by definition of the partition between the core of the data (one cluster) and the noise using the mclustBIC function of the mclust R package. Clustering was carried out in two dimensions for cases versus controls on the basis of the relative contribution of the first two PCA vectors.
DNA capturing and next-generation sequencing. Illumina HiSeq2500 (non-repetitive regions)
. DNA capturing of all three susceptibility loci 4 was done with a customized Nextera target-enrichment system (Illumina). For all loci, the given risk haploblock and the adjacent 5′ and 3′ haploblocks were captured, for a total target size of 993 kb (library size, 500 bp; 2,614 Nextera probes with a predicted average coverage of the target regions of 95%: chr1:11,023,000-11,088,000 (171 probes); chr10:64,252,000-64,967,000 (1,882 probes); chr15:40,203,000-40,416,000 (561 probes)). Repetitive regions such as GGAA microsatellites were omitted in the Nextera design. Constitutional DNA was captured from 343 Ewing sarcoma cases and 251 controls. In addition, DNA from 14 Ewing sarcoma cell lines was captured. Massive parallelend deep sequencing was done in an Illumina HiSeq2500 instrument (rapid mode; 150/150 nt) yielding a median capturing rate of 91.35% with at least 10× across samples and target regions and a median read depth per sample of 217× (Supplementary Fig. 6 ).
Illumina MiSeq (GGAA microsatellites). The mSat2 region was amplified by PCR with the primers listed in the Supplementary Data and Phusion HighFidelity DNA polymerase (Thermo Scientific). After barcoding (Fluidigm), massive parallel-end deep sequencing was done in an Illumina MiSeq instrument (300/300 nt). Paired-end reads were merged using SeqPrep tools with the default parameters (median coverage, 124×).
Variant calling, genotyping, and statistical assessment. HiSeq reads were mapped on hg19 (NCBI GhR36 build) using BWA 0.6.2 with up to 4% mismatches allowed. BAM files were preprocessed according to the recommendations of the Genome Analysis Toolkit (GATK) using Samtools 1.8 (ref. 49) , Picard tools 1.97 and GATK2.2. 16 (ref. 50) . Variant calling was done with GATK, focusing on single-nucleotide variants (SNVs) supported by ≥2 identical alternative reads at positions with ≥10× in 90% of the samples. Genotype calling was done with the GATK DepthOfCoverage function. SNVs were defined as homozygous if the alternative allele ratio (AAR) was <0.2 or >0.8, whereas heterozygous SNVs were defined by an AAR within ± 2 s.d. of the mean AAR of the non-homozygous SNVs. SNVs that had a minor allele frequency of >0.05 and that did not depart from Hardy-Weinberg equilibrium in the entire cohort were considered for further analyses. Regional association results were plotted using LocusZoom 51 . The workflow is summarized in Supplementary Figure 7 .
Association testing and analysis of LD. Statistical differences in genotype distributions were assessed with a logistic regression. Associations were adjusted for significant PCA eigenvectors (EV1, EV5 and EV6). P values were adjusted by false discovery rate. Significantly different SNVs were annotated with information available from the dbSNPv137 and RefGene databases using ANNOVAR v2013. LD and haplotype analyses were done with PLINK and HaploView 52,53 as described by Gabriel et al. 54 . Association testing conditional to rs79965208 npg
